Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual

Summary

Patients with chronic hepatitis genotype 1b, who are intolerant or ineligible to Interferon alfa therapy with or without Ribavirin, will be treated for 24 weeks with Daclatasvir (DCV) Dual regimen (= Daclatasvir + Asunaprevir) and followed for an additional 24 weeks post-treatment in order to determine the safety and efficacy of the DCV DUAL regimen

Timeline

Start

2014-02-28

Primary completion

2015-07-31

Completion

2015-07-31

Drugs

Indications